Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Altria Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Altria Group Inc trades at $65.07 (market cap $114.13B). The key difference: Altria Group Inc is far larger — about 22.6× ACADIA Pharmaceuticals Inc.'s market cap, and Altria Group Inc pays a 6.2% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MO | |
|---|---|---|
Market Cap | $5.06B | $114.13B |
Sector | Health | Consumer Staples |
52-Week High | $29.39 | $74.92 |
52-Week Low | $20.06 | $54.72 |
Enterprise Value | $4.18B | $136.34B |
Dividend Yield | — | 6.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Altria Group (MO) trades at $68.35, up 0.89% with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains strong profitability with 39% net income margin and $6.95B net income for 2025, though revenue declined slightly to $20.14B. Recent earnings show alternating beats and misses, with Q3 2026 results pending. Analyst consensus remains bullish with 61.5% buy ratings and $71.50 price target, while the stock offers a 6.3% dividend yield with 56 consecutive annual increases expected.
MO presents value opportunity with 14.4x P/E ratio and strong cash flow generation, but faces headwinds from cigarette volume declines and regulatory pressures. The smoke-free product transition shows progress but remains early stage. Current price near support at $67 suggests limited downside, while analyst targets indicate 4.6% upside potential. Key risks include litigation exposure and slower-than-expected diversification from traditional tobacco products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
